Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In this editorial, we outline the rationale for a new approach to the assessment of airway disease based on measurement of airway inflammation using noninvasive markers (inflammometry). Our focus is on measurement of exhaled nitric oxide (FE(NO)), as this technique is simple and affordable, and is applicable in a wide variety of clinical settings. Studies have shown that raised FE(NO) is a useful marker of corticosteroid-responsive airway disease; low FE(NO) may identify patients who can safely reduce or withdraw corticosteroids. However, the optimum use of FE(NO) in clinical practice remains to be established.

Original publication




Journal article


Expert Rev Respir Med

Publication Date





107 - 111